advertisement

Diabetes

14 July 2010

Glaxo withheld info on Avandia risks

UK pharmaceutical giant GlaxoSmithKline kept the dangers of its top-selling diabetes drug Avandia out of the public eye and ghostwrote scientific articles about it, lawmakers say.

UK pharmaceutical giant GlaxoSmithKline kept the dangers of its top-selling diabetes drug Avandia out of the public eye and ghostwrote scientific articles about it, US lawmakers charged Tuesday.
 


The damning letter and the allegations in the Wall Street Journal came as a panel of experts began considering whether Glaxo's star diabetes drug should be pulled from the market.

"The documents we uncovered in our investigation will help arm the FDA with the best information possible as it evaluates Avandia's safety," Baucus said.

The FDA is not bound by recommendations made by the panels of experts it convenes to take a decision on a drug, but usually follows their advice. - (Sapa, July 2010)

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Diabetes expert

Dr. May currently works as a fulltime endocrinologist and has been in private practice since 2004. He has a variety of interests, predominantly obesity and diabetes, but also sees patients with osteoporosis, thyroid disorders, men's health disorders, pituitary and adrenal disorders, polycystic ovaries, and disorders of growth. He is a leading member of several obesity and diabetes societies and runs a trial centre for new drugs.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules